Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out

J Clin Oncol. 2018 Mar 20;36(9):837-840. doi: 10.1200/JCO.2017.76.5610. Epub 2018 Feb 1.

Authors

Rune A W van de Wetering¹, Stefan Sleijfer¹, Darren R Feldman¹, Samuel A Funt¹, George J Bosl¹, Ronald de Wit¹

Affiliation

¹ Rune A.W. van de Wetering and Stefan Sleijfer, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands; Darren R. Feldman, Samuel A. Funt, and George J. Bosl, Memorial Sloan Kettering Cancer Center, New York, NY; and Ronald de Wit, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.

No abstract available

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Carboplatin / administration & dosage*
Carboplatin / adverse effects
Chemotherapy, Adjuvant
Humans
Male
Neoplasm Staging
Seminoma / drug therapy*
Seminoma / radiotherapy
Testicular Neoplasms / drug therapy*

Substances

Antineoplastic Agents
Carboplatin

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States